Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The safety and effectiveness of pneumonectomy in non-small cell lung cancer (NSCLC) patients receiving neoadjuvant immunotherapy have not been specifically studied despite the significant outcomes seen in the neoadjuvant immunotherapy of NSCLC. This article aims to investigate the safety and efficacy in such cases.
Methods: We retrospectively analyzed NSCLC patients who underwent pneumonectomy at Zhongshan Hospital of Fudan University from 2014 to 2022 and divided them into the no-induction therapy group and the induction therapy group. We focused on surgical safety and patient prognosis after neoadjuvant immunotherapy. Package MatchIt in the R was utilized to conduct propensity score matching (PSM) for confounding variables elimination. We compared the prognosis between the two groups with Kaplan-Meier (K-M) survival analysis. Student's -test was used to analyze the differences in postoperative complications between the two groups.
Results: We involved 149 NSCLC patients who underwent pneumonectomy, 32 of whom received neoadjuvant therapy, including neoadjuvant chemotherapy or chemotherapy combined with immunotherapy. The stage of the patients was significantly reduced by the induction therapy. When compared to single chemotherapy, patients treated with immunotherapy received a more dramatic reduction. After conducting PSM analysis, we discovered that patients treated with neoadjuvant therapy who underwent pneumonectomy had a slightly better prognosis compared to untreated patients, meanwhile with no increasing in the surgical morbidity and mortality. Furthermore, we observed that neoadjuvant immunotherapy combined with chemotherapy resulted in a better prognosis than chemotherapy alone.
Conclusions: In our research, we proved that pneumonectomy following neoadjuvant immunotherapy combined with chemotherapy, was safe, and effective, which also brought survival benefits to locally advanced central NSCLC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170115 | PMC |
| http://dx.doi.org/10.21037/jtd-24-1923 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.
Ann Surg Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.
View Article and Find Full Text PDFImpact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study.
Cancer Immunol Immunother
September 2025
Guangdong Provincial Clinical Research Center for Cancer, State Key Laboratory of Oncology in South China, Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangdong Esophageal Cancer Institute, Guangzhou, 510060, China.
Background: Previous studies indicated that over-dissection of lymph nodes might impair the efficacy of immunotherapy. This study aims to explore the prognostic value of ypN + status and the impact of lymph node dissection (LND) on survival after neoadjuvant immunochemotherapy (NICT) for esophageal squamous cell cancer (ESCC).
Methods: This double-center retrospective study enrolled 206 consecutive ESCC patients who underwent NICT followed by esophagectomy between 2018 and 2024.
Artificial intelligence in medical imaging empowers precision neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
J Immunother Cancer
September 2025
CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China
Neoadjuvant immunochemotherapy (nICT) has demonstrated significant potential in improving pathological response rates and survival outcomes for patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, substantial interindividual variability in therapeutic outcomes highlights the urgent need for more precise predictive tools to guide clinical decision-making. Traditional biomarkers remain limited in both predictive performance and clinical feasibility.
View Article and Find Full Text PDFNeoadjuvant Versus Adjuvant Therapy for Metaplastic Breast Cancer: Insights from the National Cancer Database-Is There a Winning Strategy?
Ann Surg Oncol
September 2025
Department of Surgery,Division of Breast Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: This study analyzed a large national cohort to compare treatment strategies and survival outcomes in metaplastic breast cancer (MtBC), a rare and aggressive subtype with poor treatment response.
Patients And Methods: Adult female patients with MtBC diagnosed between 2006 and 2021 were identified from the National Cancer Database and grouped by chemotherapy sequence (neoadjuvant vs. adjuvant) to evaluate clinical characteristics and survival outcomes.
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Cancer
September 2025
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.
Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.